Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2017.0177PMID 28520829PMCID PMC5710334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of two correlated ROC curves at a given specificity or sensitivity level

  2016cited by this paper
• Pricing in the Market for Anticancer Drugs.

  2015cited by this paper
• Prostate cancer: Improving early detection—can PCA3 do more?

  2015cited by this paper
• A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

  2015cited by this paper
• Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

  2015cited by this paper
• Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

  2014cited by this paper
• Radical prostatectomy or watchful waiting in early prostate cancer.

  2014cited by this paper
• Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy.

  2014cited by this paper
• The cost implications of prostate cancer screening in the Medicare population

  2014cited by this paper
• Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

  2014cited by this paper
• Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

  2013cited by this paper
• Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer

  2013cited by this paper
• Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

  2013cited by this paper
• PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

  2013cited by this paper
• Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

  2012cited by this paper
• Radical prostatectomy versus observation for localized prostate cancer.

  2012cited by this paper
• Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.

  2012cited by this paper
• The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

  2012cited by this paper
• The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance

  2012cited by this paper
• Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

  2011cited by this paper
• A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

  2011cited by this paper
• Lifetime economic burden of prostate cancer

  2011cited by this paper
• Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.

  2011cited by this paper
• Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.

  2011cited by this paper
• Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

  2010cited by this paper
• NCCN clinical practice guidelines in oncology: prostate cancer early detection.

  2010cited by this paper
• Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

  2009cited by this paper
• Mortality results from a randomized prostate-cancer screening trial.

  2009cited by this paper
• Mortality Results from a Randomized ProstateCancer Screening Trial

  2009cited by this paper
• PCA3: a molecular urine assay for predicting prostate biopsy outcome.

  2008cited by this paper
• Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design

  2008cited by this paper
• Fusion in the ETS gene family and prostate cancer

  2008cited by this paper
• Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer

  2007cited by this paper
• PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

  2007cited by this paper
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

  2006cited by this paper
• Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

  2006cited by this paper
• 20-year outcomes following conservative management of clinically localized prostate cancer.

  2005cited by this paper
• 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

  2004cited by this paper
• DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

  2003cited by this paper
• Kernel estimators of the ROC curve are better than empirical

  1999cited by this paper
• DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

  1999cited by this paper
• Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

  1997cited by this paper
• Density Estimation for Statistics and Data Analysis

  1987cited by this paper
• Density Estimation for Statistics and Data Analysis

  1987cited by this paper
• Cáncer

  1939cited by this paper

• Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate Cancer.

  2026cites this paper
• Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions.

  2025cites this paper
• A sensitive and specific non-invasive urine biomarker panel for prostate cancer detection

  2025cites this paper
• The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer

  2025cites this paper
• Identification of TMEM100’s role in immune infiltration regulation and construction of an endogenous RNA network in prostate cancer through pan-cancer analysis

  2025cites this paper
• Influence function-based empirical likelihood for area under the receiver operating characteristic curve in presence of covariates

  2025cites this paper
• Urinary Markers for Prostate Cancer: State of the Art

  2025cites this paper
• Electronic nose technology in the diagnosis of prostate cancer

  2025cites this paper
• The Impact of Urine Biomarkers for Prostate Cancer detection - A Systematic State of the Art Review.

  2025cites this paper
• Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow

  2025cites this paper
• Usefulness of urinary biomarker-based risk score and multiparametric MRI for clinically significant prostate cancer detection in biopsy-naïve patients

  2025cites this paper
• Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response

  2025cites this paper
• SWI/SNF chromatin remodelers in prostate cancer progression

  2024cites this paper
• Diagnostic potential of exosomal extracellular vesicles in oncology

  2024cites this paper
• Chimeric SFT2D2‐TBX19 Promotes Prostate Cancer Progression by Encoding TBX19‐202 Protein and Stabilizing Mitochondrial ATP Synthase through ATP5F1A Phosphorylation

  2024cites this paper
• Discovery of RNA Biomarkers for Prostate Cancer Using Cross-Platform Transcriptomics

  2024cites this paper
• Advancements in Biomarkers of Prostate Cancer: A Review

  2024cites this paper
• From microscopes to molecules: The evolution of prostate cancer diagnostics

  2024cites this paper
• Unveiling potential: urinary exosomal mRNAs as non-invasive biomarkers for early prostate cancer diagnosis

  2024cites this paper
• Advances in multiparametric magnetic resonance imaging combined with biomarkers for the diagnosis of high-grade prostate cancer

  2024cites this paper
• Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer

  2024cites this paper
• Prostate cancer biomarkers: from early diagnosis to precision treatment

  2024cites this paper
• Molecular diagnostics of prostate cancer: impact of molecular tests

  2024cites this paper
• Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting

  2024cites this paper
• Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer

  2024cites this paper
• Urine Biomarkers in the Management of Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review

  2023cites this paper
• Clinical Biofluid Assays for Prostate Cancer

  2023cites this paper
• miRNA Expression Patterns in Early- and Late-Stage Prostate Cancer Patients: High-Throughput Analysis

  2023cites this paper
• Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds.

  2023cites this paper
• Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification

  2023cites this paper
• Gene-Based Tests for Screening, Detection, and Management of Prostate or Bladder Cancer

  2023cites this paper
• Detection of urological cancers by the signature of organic volatile compounds in urine, from dogs to electronic noses

  2023cites this paper
• Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer

  2023cites this paper
• Clinical analysis of EV‐Fingerprint to predict grade group 3 and above prostate cancer and avoid prostate biopsy

  2023cites this paper
• EARLY DETECTION OF PROSTATE CANCER: AUA/SUO GUIDELINE

  2023cites this paper
• Long non-coding RNA DINO promotes cisplatin sensitivity in lung adenocarcinoma via the p53-Bax axis

  2023cites this paper
• Engineering the MoS2/MXene Heterostructure for Precise and Noninvasive Diagnosis of Prostate Cancer with Clinical Specimens

  2023cites this paper
• Recent Progress on Exosomes in the Diagnosis of Prostate Cancer

  2023cites this paper
• Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection

  2023cites this paper
• Covariate‐specific evaluation of continuous biomarker

  2023cites this paper
• Interval estimation for operating characteristic of continuous biomarkers with controlled sensitivity or specificity.

  2023cites this paper
• Targeted Search for Individualized Clinical Decision Rules to Optimize Clinical Outcomes

  2022influential citation
• Urinary exosomal prostate‐specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles

  2022cites this paper
• Molecular Biomarkers for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis

  2022influential citation
• Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update

  2022cites this paper
• Accuracy of novel urinary biomarker tests in the diagnosis of prostate cancer: A systematic review and network meta-analysis

  2022cites this paper
• Prospective evaluation of the role of imaging techniques and TMPRSS2:ERG mutation for the diagnosis of clinically significant prostate cancer

  2022influential citation
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection Version 1 . 2022 —

  2022cites this paper
• LINEAR BIOMARKER COMBINATION FOR CONSTRAINED CLASSIFICATION.

  2022cites this paper
• Integrated analysis of mRNA-single nucleotide polymorphism-microRNA interaction network to identify biomarkers associated with prostate cancer

  2022cites this paper
• A novel platform using homobifunctional hydrazide for enrichment and isolation of urinary circulating RNAs

  2022cites this paper
• The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases

  2022cites this paper
• Prostate cancer detection: a systematic review of urinary biosensors

  2022cites this paper
• Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need.

  2021cites this paper
• Advances in the selection of patients with prostate cancer for active surveillance

  2021cites this paper
• PCA3 in Prostate Cancer.

  2021cites this paper
• Urinary Biomarkers in Tumors: An Overview.

  2021cites this paper
• The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology.

  2021cites this paper
• Prostate cancer management in the era of COVID‐19: Recommendations from the Hong Kong Urological Association and Hong Kong Society of Uro‐oncology

  2021cites this paper
• Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis

  2021cites this paper
• Covariate adjustment in continuous biomarker assessment

  2021cites this paper
• Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review

  2021influential citation
• Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.

  2021cites this paper
• The need of avoiding unnecessary biopsies in active surveillance for prostate cancer.

  2021cites this paper
• Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis

  2021cites this paper
• Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study

  2021cites this paper
• Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions

  2021cites this paper
• Review on Recent Advances in Urinary Biomarkers Based Electrochemical Sensors for Prostate Cancer Detection

  2021cites this paper
• Downregulation of LINC01296 suppresses non-small-cell lung cancer via targeting miR-143-3p/ATG2B.

  2021cites this paper
• The need of avoiding unnecessary biopsies in active surveillance for prostate cancer.

  2021cites this paper
• Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen.

  2021cites this paper
• A Multivariate Diagnostic Model Based on Urinary EpCAM-CD9-Positive Extracellular Vesicles for Prostate Cancer Diagnosis

  2021cites this paper
• Liquid biopsy in prostate cancer: current status and future challenges of clinical application

  2021influential citation
• Current biomarkers of prostate cancer

  2021cites this paper
• Evaluating liquid biopsies for methylomic profiling of prostate cancer

  2020cites this paper
• Identification of transcription factor co-regulators that drive prostate cancer progression

  2020cites this paper
• Definition and review on a category of long non-coding RNA: Atherosclerosis-associated circulating lncRNA (ASCLncRNA)

  2020cites this paper
• Urinary glycoproteins associated with aggressive prostate cancer

  2020cites this paper
• Adding Rigor to Biomarker Evaluations—EDRN Experience

  2020cites this paper
• Active surveillance in prostate cancer management: where do we stand now?

  2020cites this paper
• Reply

  2020cites this paper
• MiR-30b-3p and miR-126-3p of urinary extracellular vesicles could be new biomarkers for prostate cancer

  2020cites this paper
• Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies

  2020cites this paper
• Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review

  2020cites this paper
• Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.

  2020cites this paper
• Use of the MyProstateScore (MPS) Test to Rule Out Clinically-Significant Cancer: Validation of a Straightforward Clinical Testing Approach.

  2020cites this paper
• Targetable gene fusions and aberrations in genitourinary oncology

  2020cites this paper
• Challenges and Opportunities of Genomic Approaches in Therapeutics Development.

  2020cites this paper
• Non-coding RNAs: the new central dogma of cancer biology

  2020cites this paper
• Diagnostic value of PCA3, TMPRSS2:ERG and prostatic specific antigen derivatives in the detection of prostate cancer

  2020cites this paper
• Advances in the diagnostic options for prostate cancer

  2020cites this paper
• Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

  2020cites this paper
• Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes

  2020influential citation
• Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice.

  2020cites this paper
• The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

  2020cites this paper
• Genome-wide analyses of transcription factors and co-regulators across seven cohorts identified reduced PPARGC1A expression as a driver of prostate cancer progression

  2020cites this paper
• Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice

  2020cites this paper
• The genetic landscapes of urological cancers and their clinical implications in the era of high‐throughput genome analysis

  2020cites this paper
• How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?

  2020cites this paper
• Beyond PSA: The Role of Prostate Health Index (phi)

  2020cites this paper